Journal Sentinel beat writer shares thoughts on Wisconsin's blowout loss to Nebraska Journal Sentinel beat writer John Steppe shares some quick thoughts following the Wisconsin Badgers' 90-60 loss to ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Journal Sentinel preps reporter Zac Bellman previews the matchups of seven area football teams still alive in the WIAA playoffs entering Nov. 14. 2025 Fantasy Football Rankings: Justin Boone's top ...

Journal Sentinel beat writers Mark Stewart and John Steppe break down Wisconsin athletic director Chris McIntosh's decision to retain Luke Fickell.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Abstract: Numerous studies have proposed hardware architectures to accelerate sparse matrix multiplication, but these approaches often incur substantial area and power overhead, significantly ...